Patient Preference in Epilepsy Monotherapy: A Non-interventional Study
Research type
Research Study
Full title
Patient Preference in Epilepsy Monotherapy - A Non-interventional Study of Vimpat® (Lacosamide) and other AEDs in the treatment of Partial onset seizures Including a Discrete Choice Experiment Surrounding Actual Treatment Decisions and Experiences
IRAS ID
226181
Contact name
John Paul Leach
Contact email
Sponsor organisation
UCB BIOSCIENCES GmbH
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
There is limited real world data available on lacosamide (LCM; Vimpat® ) monotherapy in medical practice for the treatment of partial onset seizures. LCM monotherapy refers to treating patients with a single drug (i.e. only LCM and no other combination drug). As one of the primary aims, this is the first prospective real world study collecting data on patients treated with LCM monotherapy, designed to expand the knowledge base after launch of LCM as monotherapy in the European Union (EU). This study will collect information on Anti-epileptic drug (AED) effectiveness, cognitive functioning (using EpiTrack® ),quality of life, and patient comorbidities, as well as safety, in patients on LCM monotherapy. The study will also collect data on other AED monotherapy. Analysis of the data from this study will provide real world insight into individual AED monotherapy treatment of partial-onset seizures in relation to important patient characteristics.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
17/NW/0284
Date of REC Opinion
5 May 2017
REC opinion
Favourable Opinion